TY - JOUR T1 - Extracorporeal membrane oxygenation in COVID-19 patients and in-hospital mortality: results from the Brazilian Registry using a propensity score matched analysis JF - medRxiv DO - 10.1101/2021.05.05.21256475 SP - 2021.05.05.21256475 AU - Daniela Ponce AU - Milena Soriano Marcolino AU - Magda Carvalho Pires AU - Rafael Lima Rodrigues de Carvalho AU - Heloisa Reniers Vianna AU - Matheus Carvalho Alves Nogueira AU - Fernando Antonio Botoni AU - Fernando Graça Aranha AU - André Soares de Moura Costa AU - Giovanna Grunewald Vietta AU - Felipe Ferraz Martins Graça Aranha AU - Maria Clara Pontello Barbosa Lima AU - Ana Paula Beck da Silva Etges AU - Antonio Tolentino Nogueira de Sá AU - Luana Martins Oliveira AU - Carisi Anne Polanczyk Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/07/2021.05.05.21256475.abstract N2 - Around 5% of coronavirus disease 2019 (COVID-19) patients develop critical disease, with severe pneumonia and acute respiratory distress syndrome (ARDS). In these cases, extracorporeal membrane oxygenation (ECMO) may be considered when conventional therapy fails. This study aimed to assess the clinical characteristics and in-hospital outcomes of COVID-19 patients with ARDS refractory to standard lung-protective ventilation and pronation treated with ECMO support and to compare them to patients who did not receive ECMO. Patients were selected from the Brazilian COVID-19 Registry. At the moment of the analysis, 7,646 patients were introduced in the registry, eight of those received ECMO support (0.1%). The convenience sample of patients submitted to ECMO was compared to control patients selected by genetic matching for gender, age, comorbidities, pronation, ARDS and hospital, in a 5:1 ratio. From the 48 patients included in the study, eight received ECMO and 40 were matched controls. There were no significant differences in demographic, clinical and laboratory characteristics. Mortality was higher in the ECMO group (n = 7; 87.5%) when compared with controls (n = 17; 42.5%), (p=0.048). In conclusion, COVID 19 patients with ARDS refractory to conventional therapy who received ECMO support had worse outcomes to patients who did not receive ECMO. Our findings are not different from previous studies including a small number of patients, however there is a huge difference from Extracorporeal Life Support Organization results, which encourages us to keep looking for our best excellence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by Minas Gerais State Agency for Research and Development (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais) [grant number APQ-00208-20] and National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliacao de Tecnologias em Saude)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq) [grant number 465518/2014-1]. The sponsors had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publicationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived owing to the pandemic situation and the use of deidentified data, based on medical chart review only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. ER -